Advanced in WT1-Related Wilms Tumor Syndromes

Dr. Richard C. Lauer

Hematology Oncology | Hematology | Oncology
Albuquerque, NM 

Advanced in WT1-Related Wilms Tumor Syndromes
Albuquerque, NM 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Richard Lauer is a Hematologist Oncology specialist and a Hematologist in Albuquerque, New Mexico. Dr. Lauer is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Familial Prostate Cancer, Renal Cell Carcinoma (RCC), Multiple Myeloma, and Prostate Cancer.

His clinical research consists of co-authoring 11 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in NM
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Albuquerque, NM 87106
Call: 505-272-4946

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


5 Clinical Trials

A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 19, 2025
Intervention Type: Drug
Study Drugs: TAK-700, Bicalutamide
Study Phase: Phase 3
Phase Ib/II Study of Neoadjuvant Pembrolizumab With Gemcitabine-Cisplatin (Cisplatin-Eligible) or Gemcitabine (Cisplatin-Ineligible) in Subjects With T2-4aN0M0 Urothelial Cancer: HCRN GU14-188
Phase Ib/II Study of Neoadjuvant Pembrolizumab With Gemcitabine-Cisplatin (Cisplatin-Eligible) or Gemcitabine (Cisplatin-Ineligible) in Subjects With T2-4aN0M0 Urothelial Cancer: HCRN GU14-188
Enrollment Status: Completed
Publish Date: March 18, 2025
Intervention Type: Drug, Procedure
Study Drugs: Pembrolizumab, Gemcitabine, Cisplatin
Study Phase: Phase 1/Phase 2
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Procedure, Drug
Study Drugs: Cabozantinib S-Malate, Crizotinib, Savolitinib, Sunitinib Malate
Study Phase: Phase 2
A Randomized, Double-blinded, Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer: Hoosier Cancer Research Network GU14-182
A Randomized, Double-blinded, Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer: Hoosier Cancer Research Network GU14-182
Enrollment Status: Completed
Publish Date: September 30, 2022
Intervention Type: Other, Drug
Study Phase: Phase 2
A Phase 2 Open-label Study to Evaluate the Efficacy and Safety of Seviteronel in Subjects With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone
A Phase 2 Open-label Study to Evaluate the Efficacy and Safety of Seviteronel in Subjects With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone
Enrollment Status: Completed
Publish Date: February 01, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

11 Total Publications

Dysregulation of the PRUNE2/PCA3 genetic axis in human prostate cancer: from experimental discovery to validation in two independent patient cohorts.
Dysregulation of the PRUNE2/PCA3 genetic axis in human prostate cancer: from experimental discovery to validation in two independent patient cohorts.
Journal: eLife
Published: July 16, 2022
View All 11 Publications
Similar Doctors
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Muhammad A. Tarakji
Hematology Oncology | Hematology | Oncology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Muhammad A. Tarakji
Hematology Oncology | Hematology | Oncology

Southwest Medical Associates, LLC

715 Dr Martin Luther King Jr Ave Ne, Suite 102, 
Albuquerque, NM 
 (2.2 miles away)
505-727-3040
Languages Spoken:
English, French, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Muhammad Tarakji is a Hematologist Oncology specialist and a Hematologist in Albuquerque, New Mexico. Dr. Tarakji is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Monoclonal Gammopathy of Undetermined Significance (MGUS), Acute Mountain Sickness, Familial Pancreatic Cancer, and Clear Cell Sarcoma. Dr. Tarakji is currently accepting new patients.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Neda Hashemi-Sadraei
Hematology Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Neda Hashemi-Sadraei
Hematology Oncology

Unm Medical Group Inc

2211 Lomas Blvd Ne, 
Albuquerque, NM 
 (2.1 miles away)
505-272-2111
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Neda Hashemi-Sadraei is a Hematologist Oncology provider in Albuquerque, New Mexico. Dr. Hashemi-Sadraei is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Chromophobe Renal Cell Carcinoma, Clear Cell Sarcoma, WT1-Related Wilms Tumor Syndromes, and Prostate Cancer.

Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Annette C. Fontaine
Oncology | Hematology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Annette C. Fontaine
Oncology | Hematology

New Mexico Oncology Hematology Consultants Ltd

4901 Lang Ave Ne, 
Albuquerque, NM 
 (8.2 miles away)
Languages Spoken:
English, French, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Annette Fontaine is an Oncologist and a Hematologist in Albuquerque, New Mexico. Dr. Fontaine is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Familial Colorectal Cancer, Bone Marrow Aspiration, and Salpingo-Oophorectomy. Dr. Fontaine is currently accepting new patients.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lauer's expertise for a condition
ConditionClose
    • Distinguished
    • Familial Prostate Cancer
      Dr. Lauer is
      Distinguished
      . Learn about Familial Prostate Cancer.
      See more Familial Prostate Cancer experts
    • Advanced
    • Chromophobe Renal Cell Carcinoma
      Dr. Lauer is
      Advanced
      . Learn about Chromophobe Renal Cell Carcinoma.
      See more Chromophobe Renal Cell Carcinoma experts
    • Clear Cell Sarcoma
      Dr. Lauer is
      Advanced
      . Learn about Clear Cell Sarcoma.
      See more Clear Cell Sarcoma experts
    • Familial Wilms Tumor 2
      Dr. Lauer is
      Advanced
      . Learn about Familial Wilms Tumor 2.
      See more Familial Wilms Tumor 2 experts
    • Multiple Myeloma
      Dr. Lauer is
      Advanced
      . Learn about Multiple Myeloma.
      See more Multiple Myeloma experts
    • Prostate Cancer
      Dr. Lauer is
      Advanced
      . Learn about Prostate Cancer.
      See more Prostate Cancer experts
    • Renal Cell Carcinoma (RCC)
      Dr. Lauer is
      Advanced
      . Learn about Renal Cell Carcinoma (RCC).
      See more Renal Cell Carcinoma (RCC) experts
    View All 8 Advanced Conditions
    • Experienced
    • Acute Mountain Sickness
      Dr. Lauer is
      Experienced
      . Learn about Acute Mountain Sickness.
      See more Acute Mountain Sickness experts
    • Adult Immune Thrombocytopenia
      Dr. Lauer is
      Experienced
      . Learn about Adult Immune Thrombocytopenia.
      See more Adult Immune Thrombocytopenia experts
    • Adult Soft Tissue Sarcoma
      Dr. Lauer is
      Experienced
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    • ALK-Positive Non-Small Cell Lung Cancer
      Dr. Lauer is
      Experienced
      . Learn about ALK-Positive Non-Small Cell Lung Cancer.
      See more ALK-Positive Non-Small Cell Lung Cancer experts
    • Anal Cancer
      Dr. Lauer is
      Experienced
      . Learn about Anal Cancer.
      See more Anal Cancer experts
    • Anaplastic Thyroid Cancer
      Dr. Lauer is
      Experienced
      . Learn about Anaplastic Thyroid Cancer.
      See more Anaplastic Thyroid Cancer experts
    View All 105 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2025 All Rights Reserved